1st patient dosed in AIPAC-003 ph2/3 breast cancer trial
Filed with ASX · · 2 pages · English
Earlier from Immutep
- Promising New Data in 1st line NSCLC from INSIGHT-003 Trial
- Excellent initial Overall Survival Benefit in 1st line NSCLC
- FDA supportive of Efti registrational trial in lung cancer
- Approval to start Efti & Bavencio trial in urothelial cancer
- Immutep to announce new TACTI-002 data at ASCO 2023
Later from Immutep
- Publication of Abstracts for ASCO 2023 Annual Meeting
- Charles River Laboratories to run IMP761 Toxicology Study
- A$80 million fully underwritten equity raising
- Immutep granted US patent for IMP761 agonist LAG-3 antibody
- US patent granted for Efti with PD-1 pathway inhibitor
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep